Dolutegravir 50mg Tab

DRUG3 trials

Sponsors

University Hospital Virgen de las Nieves, Michael Hoelscher, Johns Hopkins University

Conditions

HIVHIV-1-infectionOther Specified Pulmonary TuberculosisPulmonary TuberculosesTuberculosis

Phase 1

BTZ-043 - Multiple Ascending Dose (MAD) to Evaluate Safety, Tolerability and Early Bactericidal Activity (EBA)

CompletedNCT04044001

Michael HoelscherOther Specified Pulmonary Tuberculosis, Pulmonary Tuberculoses

Start: 2019-11-15End: 2022-05-31Updated: 2022-08-10

Phase 3

Dolutegravir/Lamivudine Dual Therapy for ART-naïve People With HIV and TB Receiving Rifampin-based TB Treatment

RecruitingNCT06497465

Johns Hopkins UniversityHIV, Tuberculosis

Start: 2025-09-18End: 2029-01-31Target: 150Updated: 2025-09-24

Unknown Phase

Real Life Study of Dolutegravir Plus Lamivudine in HIV-1-Infected Treatment-Naive Patients

CompletedNCT04002323

University Hospital Virgen de las NievesHIV-1-infection

Start: 2019-05-07End: 2022-03-31Updated: 2024-07-10

Related Papers

Safety, bactericidal activity, and pharmacokinetics of the antituberculosis drug candidate BTZ-043 in South Africa (PanACEA-BTZ-043-02): an open-label, dose-expansion, randomised, controlled, phase 1b/2a trial.

2025-01-079 citations